W. Hertz
Vorstandsvorsitzender bei GRI BIO, INC.
Vermögen: 23 681 $ am 30.04.2024
Profil
W.
Marc Hertz is the founder of GRI Bio Operations, Inc. He currently holds the position of President, Chief Executive Officer & Director at GRI Bio, Inc. since 2023.
Additionally, he is the Chairman at Evozym Biologics, Inc. since 2014 and Chairman at Multimeric Biotherapeutics, Inc. In his former positions, Dr. Hertz served as the Chief Executive Officer at Pharmexa, Inc., Chief Executive Officer & Director at Vallon Pharmaceuticals, Inc., and Director at Gemvax AS.
Dr. Hertz completed his undergraduate degree at Bowdoin College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GRI BIO, INC.
1,46% | 22.04.2024 | 55 072 ( 1,46% ) | 23 681 $ | 30.04.2024 |
Aktive Positionen von W. Hertz
| Unternehmen | Position | Beginn |
|---|---|---|
| GRI BIO, INC. | Vorstandsvorsitzender | 01.04.2023 |
Evozym Biologics, Inc.
 Evozym Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Evozym Biologics, Inc. develops a technology platform that utilizes evolutionary biology to transform gene profiles into novel proteins. The private company is based in Lewes, DE. The company was founded by Joseph Grzymski. Joseph Grzymski has been the CEO since incorporation. | Vorsitzender | 24.06.2014 |
Multimeric Biotherapeutics, Inc.
 Multimeric Biotherapeutics, Inc. BiotechnologyHealth Technology Multimeric Biotherapeutics, Inc. operates as a early-stage biotech company. Its products include clinical pipeline MagaVax vaccines, tumor immunotherapy, ovarian cancer immunotherapy, MegaLigands, and UltraLigands. The company was founded in 2008 and is headquartered in La Jolla, CA. | Vorsitzender | - |
GRI Operations, Inc.
 GRI Operations, Inc. BiotechnologyHealth Technology GRI Bio, Inc. develops cell based therapies for fibrotic and autoimmune diseases. Its programs are GRI-0621, GRI-0124, and GRI-0803. The company was founded by Marc Hertz, Vipin Kumar, and Albert Agro and is headquartered in La Jolla, CA. | Gründer | - |
Ehemalige bekannte Positionen von W. Hertz
| Unternehmen | Position | Ende |
|---|---|---|
| Pharmexa, Inc. | Vorstandsvorsitzender | - |
Gemvax AS
 Gemvax AS Pharmaceuticals: MajorHealth Technology Part of GemVax & KAEL Co., Ltd., Gemvax AS is a Norwegian peptide-based drug development company that focuses on researching and developing treatments for Alzheimer's disease and prostate hyperplasia. The company is based in Porsgrunn, Norway. The company also develops and sell products such as CA filters and provide investment information. The company was founded by Mona Elisabeth Møller. Gemvax was acquired by VaxOnco, Inc. from Pharmexa A/S on October 30, 2008. | Direktor/Vorstandsmitglied | - |
| GRI BIOPAR | Vorstandsvorsitzender | - |
Ausbildung von W. Hertz
| Bowdoin College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GRI BIO, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Evozym Biologics, Inc.
Evozym Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Evozym Biologics, Inc. develops a technology platform that utilizes evolutionary biology to transform gene profiles into novel proteins. The private company is based in Lewes, DE. The company was founded by Joseph Grzymski. Joseph Grzymski has been the CEO since incorporation. | Commercial Services |
Gemvax AS
Gemvax AS Pharmaceuticals: MajorHealth Technology Part of GemVax & KAEL Co., Ltd., Gemvax AS is a Norwegian peptide-based drug development company that focuses on researching and developing treatments for Alzheimer's disease and prostate hyperplasia. The company is based in Porsgrunn, Norway. The company also develops and sell products such as CA filters and provide investment information. The company was founded by Mona Elisabeth Møller. Gemvax was acquired by VaxOnco, Inc. from Pharmexa A/S on October 30, 2008. | Health Technology |
| Pharmexa, Inc. | |
Multimeric Biotherapeutics, Inc.
Multimeric Biotherapeutics, Inc. BiotechnologyHealth Technology Multimeric Biotherapeutics, Inc. operates as a early-stage biotech company. Its products include clinical pipeline MagaVax vaccines, tumor immunotherapy, ovarian cancer immunotherapy, MegaLigands, and UltraLigands. The company was founded in 2008 and is headquartered in La Jolla, CA. | Health Technology |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
GRI Operations, Inc.
GRI Operations, Inc. BiotechnologyHealth Technology GRI Bio, Inc. develops cell based therapies for fibrotic and autoimmune diseases. Its programs are GRI-0621, GRI-0124, and GRI-0803. The company was founded by Marc Hertz, Vipin Kumar, and Albert Agro and is headquartered in La Jolla, CA. | Health Technology |
